Thalidomide clinical trials
Also written Thalomid and Kevadon.
How each study uses Thalidomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Thalidomide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Jul 1998 · THALOMID · NDA 020785 (FDA, Drugs@FDA)
- European Union
- 16 Apr 2008 · Thalidomide BMS (previously Thalidomide Celgene) · EMEA/H/C/000823 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- N-phthalylglutamic acid imide
- 1
Studies by the year they started
304 studies that test it; most in 2002 (31)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1995 | 1 |
| 1996 | 2 |
| 1997 | 2 |
| 1998 | 11 |
| 1999 | 10 |
| 2000 | 21 |
| 2001 | 28 |
| 2002 | 31 |
| 2003 | 20 |
| 2004 | 16 |
| 2005 | 19 |
| 2006 | 21 |
| 2007 | 15 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 7 |
| 2013 | 10 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 8 |
| 2017 | 12 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 301
National Cancer Institute (NCI) (27) · University of Arkansas (18) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (9) · Dana-Farber Cancer Institute (8) · SWOG Cancer Research Network (7) · Institute of Hematology & Blood Diseases Hospital, China (6) · Roswell Park Cancer Institute (5)
Often tested with
Tested in the same studies.
Dexamethasone (56) · Bortezomib (27) · Cyclophosphamide (26) · Melphalan (19) · Prednisone (16) · Doxorubicin (15) · Temozolomide (13) · Etoposide (12)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Thalidomide is the comparator. A study of two new drugs counts under both.
- 1Lenalidomide · National Cancer Institute (NCI)
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test Thalidomide, phase 3 first.
- Aug 2027UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total TherapyPhase 3 · University of Arkansas
- Feb 2027A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisPhase 2 · Memorial Sloan Kettering Cancer Center
- Feb 2027The Therapeutic Effect of Thalidomide in SyringomyeliaPhase 2 · Xuanwu Hospital, Beijing
- Mar 2027Efficacy and Safety of Thalidomide for Pediatric PFAPA SyndromeNot applicable · Wenjie Zheng
- Apr 2027Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Jun 2027Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaNot applicable · Riphah International University
- Aug 2027Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Oct 20272015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyPhase 2 · University of Arkansas
- Oct 2027UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionPhase 2 · University of Arkansas
Studies
Open first, then newest update. How each study uses Thalidomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 315
- Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaRecruitingNot applicableRiphah International UniversityNCT07673302Written as Thalidomide
- The Efficacy of CAPCT in Patients With PTCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07746245Written as Thalidomide (100mg)
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid TumorsRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT07671534Written as Thalidomide
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.RecruitingPhase 2Yongquan ShiNCT06617182Written as Thalidomide
- Efficacy and Safety of Thalidomide for Pediatric PFAPA SyndromeNot yet recruitingNot applicableWenjie ZhengNCT07476625Written as Thalidomide (50mg)
- Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT PatientsRecruitingPhase 2Rongrong LiuNCT07338344Written as Luspatercept combined with low-dose thalidomide
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2/3Shanghai Zhongshan HospitalNCT07309419Written as Thalidomide (drug)
- Thalidomide for the Symptomatic Large Granular Lymphocytic LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06530576Written as Thalidomide and methotrexate
- Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07187193Written as Thalidomide (100mg)
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06793475Written as Thalidomide
- Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal CancerRecruitingPhase 2Xinqiao Hospital of ChongqingNCT06279351Written as Thalidomide+cetuximab+FOLFOX/FOLFIRI
- Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta ThalassemiaRecruitingPhase 2National Institute of Blood and Marrow Transplant (NIBMT), PakistanNCT06490627Written as Thalidomide
- Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)Not yet recruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT06772480Written as Thalidomide
- Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingPhase 2Henan Cancer HospitalNCT06231680Written as Thalidomide 50mg
- The Therapeutic Effect of Thalidomide in SyringomyeliaRecruitingPhase 2Xuanwu Hospital, BeijingNCT06268093Written as Thalidomide
- Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic CancerRecruitingPhase 3Fudan UniversityNCT06017284Written as Thalidomide
- Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMMRecruitingPhase 2Juan DuNCT04941937Written as Thalidomide
- TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLLRecruitingPhase 2/3Institute of Hematology & Blood Diseases Hospital, ChinaNCT04453345Written as thalidomide + prednisone + methotrexate
- A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT03980002Written as Ibrutinib and Thalidomide
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple MyelomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00098475Written as Thalidomide
See all 315 studies that test Thalidomide →
Given beside what is tested · 33 — Thalidomide is usual care or a partner of the new treatment
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-ThalassemiaRecruitingPhase 3Khyber Medical University PeshawarNCT07884773Written as Thalidomide
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as Thalidomide
- A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 4Tongji UniversityNCT06276933Written as Camrelizumab + chemotherapy+Thalidomide
- CURATE.AI Optimized Modulation for Multiple MyelomaRecruitingPhase 2/3National University Hospital, SingaporeNCT03759093Written as Thalidomide
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedPhase 1Janssen Research & Development, LLCNCT01998971Written as Thalidomide
- A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedPhase 3Intergroupe Francophone du MyelomeNCT02541383Written as Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
- Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney FailureTerminatedPhase 2Emory UniversityNCT04352205Written as Thalidomide
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedPhase 2Mario BoccadoroNCT02586038Written as Thalidomide
- Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerStatus unknownPhase 2Fujian Cancer HospitalNCT05266820Written as Thalidomide
- MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationTerminatedPhase 3European Society for Blood and Marrow TransplantationNCT00256776Written as Thalidomide
- Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 InsertionsStatus unknownPhase 2Shanghai Chest HospitalNCT04382300Written as pyrotinib combined with thalidomide
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownPhase 2Henan Cancer HospitalNCT02733380Written as Thalidomide
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedPhase 2Arbeitsgemeinschaft medikamentoese TumortherapieNCT02410694Written as Thalidomide
- S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisCompletedPhase 2SWOG Cancer Research NetworkNCT00064337Written as thalidomide
- Phase II Study of RT-PEPC in Relapsed Mantle Cell LymphomaCompletedPhase 2Weill Medical College of Cornell UniversityNCT00151281Written as Thalidomide
- Modified Bortezomib-based Combination Therapy for Multiple MyelomaStatus unknownPhase 4Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT02559154Written as Thalidomide
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaCompletedPhase 1/2Mayo ClinicNCT01057225Written as thalidomide
- Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple MyelomaStatus unknownPhase 3Jinling Hospital, ChinaNCT02248428Written as Thalidomide
- Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid TumorsStatus unknownPhase 1Haihe Biopharma Co., Ltd.NCT02870036Written as Thalidomide
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine TumorStatus unknownPhase 2Chinese Academy of Medical SciencesNCT03204032Written as Thalidomide
Showing 20 of 33.
As the comparator · 7 — what is tested is compared with Thalidomide
- Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 ReactionRecruitingPhase 2Medicines Development for Global HealthNCT07172659Written as Thalidomide
- Bevacizumab in the Treatment of HHTRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07828015Written as Thalidomide (50mg)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00602641Written as Thalidomide
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedPhase 3Millennium Pharmaceuticals, Inc.NCT01659658Written as Thalidomide
- Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.CompletedPhase 2National Institute of Blood and Marrow Transplant (NIBMT), PakistanNCT06239389Written as Thalidomide 100mg
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedPhase 3CelgeneNCT00689936Written as Melphalan, Prednisone and Thalidomide
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine TumorStatus unknownPhase 2Chinese Academy of Medical SciencesNCT03204019Written as Tegafur and Temozolomide combined with Thalidomide
Codes
What other systems call Thalidomide · ClinicalTrials.gg INT008299
- MeSH (NLM) D013792ThalidomideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4Z8R6ORS6LTHALIDOMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 10432Confirmed FDA, Wikidata
- Wikidata Q203174thalidomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C870ThalidomideOne source FDA
- DrugBank DB01041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D013792 | Thalidomide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4Z8R6ORS6L | THALIDOMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 10432 | — | Confirmed FDA, Wikidata |
| Wikidata | Q203174 | thalidomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C870 | Thalidomide | One source FDA |
| DrugBank | DB01041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.